Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors

Stopped early

Conditions studied: Hepatoblastoma, Hepatocellular Carcinoma, Rhabdoid Tumor of Liver, Undifferentiated (Embryonal) Sarcoma of the Liver, Pediatric Liver Cancer, Liver Tumors

In brief

This study will be performed to evaluate the Clinical Outcomes and Quality of Life after Transarterial Radioembolization with Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults with Liver Tumors. The treatment and techniques used here are well established in adults. The purpose of this study is to evaluate: 1. the response to treatment and clinical outcomes of treatment with TARE Y-90 as part of standard therapy and 2. to assess the change in the patient's quality of life before, during and after treatment with TARE-Y90

Key facts

Study ID

NCT04315883

Run by

Nemours Children's Clinic

People needed

3

Starts

2021-02-11

Expected to finish

2024-03-28

Last updated by the study team

2024-06-12

Who can join

Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Boys and girls age < 21 years of age
• History of liver tumor
• Meet criteria for treatment with TARE-Y90

You may not qualify if…

• • Inability to complete required study procedures.

Where it is running

• Nemours-AI duPont Hospital for Children — Wilmington, Delaware, United States
• Nemours Children's Specialty Care — Jacksonville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.